Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic CancerSusan Tsai, Douglas B. Evans, Ben George et al.|Annals of Surgery|2018Cited by 237
Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoodsJavier Mora, Susan Tsai, Ashley N. Krepline et al.|The American Journal of Surgery|2020Cited by 78
Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancerMohammed Aldakkak, Susan Tsai, Fabian M. Johnston et al.|HPB|2015Cited by 69
Patency Rates of Portal Vein/Superior Mesenteric Vein Reconstruction After Pancreatectomy for Pancreatic CancerAshley N. Krepline, Susan Tsai, Kathleen K. Christians et al.|Journal of Gastrointestinal Surgery|2014Cited by 51
Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancerJohn T. Miura, Susan Tsai, Ashley N. Krepline et al.|Surgery|2015Cited by 41